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We have assessed HER2 status in a large well-characterised
breast cancer series prepared as tissue microarray (n = 1858) using
IHC (HercepTest, DakoCytomation) and chromogenic ISH (CISH;
DuoCISH, DakoCytomation) in order to identify relationships with
clinico-pathological variables and patient outcome. None of these
cases have received anti-HER2 therapy.
There was excellent overall concordance between HercepTest
negative (scores 0/1+) and positive (3+) with CISH positive/nega-
tive (defined as HER2/Chr17 copy number ratio of P2; p < 0.001).
Twelve percent of cases were identified as HER2 positive (those
with 3+ HercepTest scores or 2+ with gene amplification). Of the
74 borderline HercepTest 2+ cases, 44 cases (59%) showed HER2
gene amplification. We identified that HercepTest 2+ non-ampli-
fied cases were not significantly different from those amplified
2+ or 3+ cases with respect to their clinical outcome (BCSS and
DFS).
The overall concordance between HercepTest and CISH analy-
sis for HER2 status was excellent. All HercepTest 2+ cases identi-
fied were observed to have poor outcomes similar to those
HercepTest 3+ cases regardless of gene amplification status. In
the current clinical environment, cases exhibiting IHC 2+ with
non-amplified HER2 gene status are not offered targeted HER2
therapy but do exhibit aggressive clinical behavioural characteris-
tics and therefore optimal treatment strategies for these patients
need to be determined.
doi:10.1016/j.ejcsup.2010.06.018
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Nuclear poly (ADP-ribose) polymerases (PARPs) are a family of
global monitor of chromatin structure and DNA damage repair.
The relative expression levels of PARP1 protein in estrogen recep-
tor negative (ER–ve) BC remain unclear. Therefore the aim of this
study was to investigate PARP1 protein expression in ER–ve BC
with relevance to molecular subtypes and disease outcome.
Methods: PARP1 protein expression was assessed, using immu-
nohistochemistry, in a well-characterised series of ER–ve primary
operable invasive BC cases (n = 251) with long term clinical follow-
up. Results were correlated with molecular and clinicopathologi-
cal parameters and patients’ outcome.
Results: PARP1 nuclear expression was classified as high or low
using a cut-off of 80 H-score, determined using X-Tile bio-infor-
matics software. One hundred and thirty five (53.8%) of the infor-
mative cases were classified showing high expression. Significant
positive correlation was found between PARP1 expression and
BRCA1 expression (p = 0.002) but no association was found with
p53. High PARP1 expression was observed in both basal-like
(HER2– and CK5/6 and or EGFR+) (60%) and HER2+ (64%) compared
with triple negative (TN) non-basal BC classes (45%). PARP1
expression was significantly associated with BC specific survival
(p = 0.01). When analysis was assessed by the molecular subtype,
the association of PARP1 expression with improved survival was
restricted to TN tumours.
Conclusion: We have observed a positive correlation between
PARP1 protein expression and BRCA1 expression. Although high
PARP1 expression is seen in ER–/HER+ and HER– tumours, its
association with survival was only found in the ER–/HER2– sub-
type. Thus, its targeted inhibition may particularly benefit
patients with TN BC.
doi:10.1016/j.ejcsup.2010.06.019
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Background: Tissue micro-arrays (TMA) are increasingly used to
generate data for studies of tumourmolecular phenotypehowever,
TMA data are particularly prone tomissingness. Avariety ofmeth-
ods to deal withmissing data are available; these have been exten-
sively evaluated using simulated data, but there has been no
empirical evaluations of these methods using real TMA data.
Methods: We pooled data from over 11,000 cases of invasive
breast cancer from five studies that collected information on
seven prognostic indicators including four molecular markers,
together with survival time data. We compared the results of a
multi-variate Cox regression using complete case analysis
(CCA), mean substitution (MS) and multiple imputation (MI). We
also performed an analysis in which missing data were simulated
under different assumptions.
Results: Over half the cases had data on at least one of the
seven variables and 10.5% had missing data on 4 or more. The
hazard ratio estimates based on multiple imputation and mean
substitution, were similar with similar standard errors. Hazard
ratio estimates and confidence intervals (Table). The results from
CCA were less precise (wider confidence limits). Accuracy of the
estimates was based on the simulated data with CCA having
the least accurate results.
Hazard ratios and confidence intervals using mean substitution
and multiple imputation.
Method ER status PR status HER2 status BCL2 status
Multiple
imputation
– HR (CIs)
0.43
(.35–54)
0.39
(.30–.50)
1.25
(1.13–1.40)
0.85
(.76–.96)
Mean
substitution
– HR (CIs)
0.40
(.32–.49)
0.37
(.29–.46)
1.31
(1.17–1.46)
0.82
(.74–.92)
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